The use of biomaterials in delivering CRISPR/Cas9 for gene therapy in infectious diseases
holds tremendous potential. This innovative approach combines the advantages of …

Therapeutic genome editing has the potential to cure diseases by directly correcting genetic
mutations in tissues and cells. Recent progress in the clustered regularly interspaced short …

Extracellular vesicles (EVs) have emerged as a promising platform for gene delivery owing
to their natural properties and phenomenal functions, being able to circumvent the …

Hereditary hearing loss (HHL) is a neurosensory disorder that affects every 1/500 newborns
worldwide and nearly 1/3 people over the age of 65. Congenital deafness is inherited as …

The clustered regularly interspaced short palindromic repeat (CRISPR) system, an emerging
tool for genome editing, has garnered significant public interest for its potential in treating …

CRISPR/Cas9 gene editing enables the treatment of hearing loss in congenitally deaf
neonatal mice via both viral and non-viral delivery. While adeno-associated virus (AAV) …

Prolonged expression of the CRISPR-Cas9 nuclease and gRNA from viral vectors may
cause off-target mutagenesis and immunogenicity. Thus, a transient delivery system is …

Cas9 ribonucleoprotein (RNP)-mediated delivery has emerged as an ideal approach for in
vivo applications. However, the delivery of Cas9 RNPs requires electroporation or lipid-or …

Hearing Loss (HL) is the most prevalent sensorineural disorder, affecting 360 million people
worldwide. As genetic causes lead to 50% of pre-lingual deafness, gene therapy is …

Small extracellular vesicles (sEVs) are naturally occurring vesicles that have the potential to
be manipulated to become promising drug delivery vehicles for on-demand in vitro and in …